Assetmark Inc. Boosts Position in AstraZeneca PLC (NASDAQ:AZN)

Assetmark Inc. increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 11.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 154,906 shares of the company’s stock after purchasing an additional 15,642 shares during the period. Assetmark Inc.’s holdings in AstraZeneca were worth $10,433,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Clearstead Advisors LLC raised its stake in shares of AstraZeneca by 15.5% in the third quarter. Clearstead Advisors LLC now owns 1,209 shares of the company’s stock valued at $82,000 after acquiring an additional 162 shares in the last quarter. Bryn Mawr Capital Management LLC increased its stake in shares of AstraZeneca by 0.3% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 61,866 shares of the company’s stock worth $4,167,000 after buying an additional 164 shares during the period. Drive Wealth Management LLC raised its holdings in AstraZeneca by 4.5% in the fourth quarter. Drive Wealth Management LLC now owns 3,911 shares of the company’s stock valued at $263,000 after acquiring an additional 170 shares in the last quarter. Glenview Trust co lifted its stake in AstraZeneca by 3.8% in the third quarter. Glenview Trust co now owns 4,724 shares of the company’s stock worth $320,000 after acquiring an additional 174 shares during the last quarter. Finally, Nordwand Advisors LLC grew its holdings in AstraZeneca by 44.5% during the 4th quarter. Nordwand Advisors LLC now owns 578 shares of the company’s stock worth $39,000 after acquiring an additional 178 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. BMO Capital Markets lifted their price target on AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday, April 26th. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $81.00.

AstraZeneca Trading Down 0.5 %

NASDAQ AZN opened at $78.80 on Thursday. The firm’s fifty day moving average price is $71.33 and its 200 day moving average price is $67.56. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $79.25. The company has a debt-to-equity ratio of 0.73, a current ratio of 0.89 and a quick ratio of 0.70. The company has a market capitalization of $244.31 billion, a price-to-earnings ratio of 38.63, a price-to-earnings-growth ratio of 1.42 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Thursday, April 25th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.08. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. The company had revenue of $12.68 billion for the quarter, compared to analyst estimates of $11.92 billion. On average, sell-side analysts expect that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.